Table 2. . Rates of transfusion avoidance and hemoglobin normalization.
| Patient-level data for transfusion avoidance from PRINCE trial [63], n (%) | ||||
|---|---|---|---|---|
| To: | From: | |||
| Transfusion required (pegcetacoplan only) | Transfusion avoidant (pegcetacoplan only) | Transfusion required (pegcetacoplan + BSC) | Transfusion avoidant (pegcetacoplan + BSC) | |
| Transfusion avoidant and Hb normalized | 10/21 (47.6) | 7/10 (70.0) | 10/32 (31.3) | 7/14 (50.0) |
| Transfusion avoidant and Hb not normalized | 9/21 (42.9) | 3/10 (30.0) | 9/32 (28.1) | 4/14 (28.6) |
| Transfusion required | 2/21 (9.5) | 0/10 (0.0) | 13/32 (40.6) | 3/14 (21.4) |
| Sum of probabilities | 100 | 100 | 100 | 100 |
| Hb normalization probabilities for transfusion avoidant group (%) | ||||
|---|---|---|---|---|
| From: | To: | |||
| Transfusion required | Transfusion avoidant | |||
| Transfusion avoidant | Hb normalized | 90.5 | 96.0 | 49.9 |
| Hb not normalized | 44.9 | |||
| Transfusion required | 9.5 | 4.0 | 4.0 | |
| Sum of probabilities | 100 | 100 | 100 | |
| Calculated transition probabilities – Hb normalization | ||||
|---|---|---|---|---|
| From: | To: | |||
| Hb normalized (%) | Hb not normalized (%) | Transfusion required (%) | ||
| Hb normalized | 50.51–53.41 | 45.46–46.59 | 0.00–4.03 | |
| Hb not normalized | 47.62–50.51 | 44.33–45.46 | 4.03–8.05 | |
| Transfusion required | 47.62 | 42.86 | 9.52 | |
BSC: Best supportive care; Hb: Hemoglobin.